回春凉膈散이 db/db 마우스의 고혈당 및 지질대사에 미치는 효과
The Effects of Hoechunyanggyeok-san on hyperglycemia and Dyslipidemia in db/db mice
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives : Hoechunyanggyeok-san (HYS) is a traditional herbal medicine, which has been clinically used for treating febrile and inflammatory diseases. HYS has been reported to be a useful treatment for diabetes, atherosclerosis and hyperlipidemia in the type 1 diabetic model. However, the mechanism of the effects of HYS against hyperglycemia and hyperlipidemia is poorly understood. In the present study, we investigated the underlying mechanism of ameliorative effect of HYS on hyperglycemia and hyperlipidemia in vivo. Methods : HYS (10, 50 mg/kg/day, p.o.) was administered every day for 2 weeks to db/db mice and its effect was compared with vehicle-treated db/db mice. To confirm serum glucose and triglyceride (TG) changes, serological testing was performed. The levels of sterol regulatory element-binding protein-1 (SREBP-1) activity and Sirtuin1 (SIRT1), AMP-activated protein kinase (AMPK), and acetyl-CoA carboxylase α (ACCα) expression were analyzed by western blot analysis. Results : The administration of HYS significantly decreased the elevated serum glucose and TG in db/db mice. HYS administration increased the levels of SIRT1 and AMPK expression compared with the vehicle-treated group. Moreover, HYS treatment significantly inhibited SREBP-1 activity and ACCα expression in the liver, while the vehicle-treated group exhibited their increase. Conclusions : In conclusion, HYS is suggested to have an improvement effect on hyperglycemia and hyperlipidemia by activating the SIRT1/AMPK signaling pathway and inhibiting SREBP-1.
Abstract
Objectives : Hoechunyanggyeok-san (HYS) is a traditional herbal medicine, which has been clinically used for treating febrile and inflammatory diseases. HYS has been reported to be a useful treatment for diabetes, atherosclerosis and hyperlipidemia in the type 1 diabetic model. However, the mechanism of the effects of HYS against hyperglycemia and hyperlipidemia is poorly understood. In the present study, we investigated the underlying mechanism of ameliorative effect of HYS on hyperglycemia and hyperlipidemia in vivo. Methods : HYS (10, 50 mg/kg/day, p.o.) was administered every day for 2 weeks to db/db mice and its effect was compared with vehicle-treated db/db mice. To confirm serum glucose and triglyceride (TG) changes, serological testing was performed. The levels of sterol regulatory element-binding protein-1 (SREBP-1) activity and Sirtuin1 (SIRT1), AMP-activated protein kinase (AMPK), and acetyl-CoA carboxylase α (ACCα) expression were analyzed by western blot analysis. Results : The administration of HYS significantly decreased the elevated serum glucose and TG in db/db mice. HYS administration increased the levels of SIRT1 and AMPK expression compared with the vehicle-treated group. Moreover, HYS treatment significantly inhibited SREBP-1 activity and ACCα expression in the liver, while the vehicle-treated group exhibited their increase. Conclusions : In conclusion, HYS is suggested to have an improvement effect on hyperglycemia and hyperlipidemia by activating the SIRT1/AMPK signaling pathway and inhibiting SREBP-1.
참고문헌 (30)
- Klop B, "Dyslipidemia in obesity: mechanisms and potential targets", Nutrients, 5, pp.1218~1240 (2013)
- 김정환, "당뇨병이 없는 성인 여성에서 혈청 visfatin 농도와 비만 및 대사증후군과의 관련성", 대한비만학회지, 18(1), pp.15~23 (2009), 대한비만학회
- Speigelman BM, "Obesity and the regulation of energy balance", Cell, 104(4), pp.531~543 (2001)
- Rodgers RJ, "Anti- obesity drugs: past, present and future", Disease Models & Mechanisms, 5, pp.621~626 (2012)
- Gong JH, "Man-byeong-hoe-chun", pp.16~ (1972), Haeng-rim -seo-won
- Hwang DY, "Bang-yak-hap-pyeon", pp.304~305 (1985), Yeong- rim-sa
- Hong JS, "Effect of Hoechounyanggeuksan on the glucose in diabetic rats induced by streptozotocin", J. of Oriental Medicine, 14, pp.397~412 (1991)
- Munehiro Kitada, "SIRT1 in Type 2 Diabetes: Mechanisms and Therapeutic Potential", Diabetes and Metabolism Journal, 37(5), pp.315~325 (2013), 대한당뇨병학회
- Kitada M, "Sirtuins and renal disease: relationship with aging and diabetic nephropathy", Clin Sci (Lond), 124, pp.153~164 (2013)
- Ruderman N, "AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome", Nat Rev Drug Discov, 3, pp.340~351 (2004)
- Lan F, "SIRT1 modulation of the acetylation status, cytosolic localization and activity of LKB1. Possible role in AMP-activated protein kinase activation", J Biol Chem, 283(41), pp.27628~27635 (2008)
- Canto C, "AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity", Nature, 458(7241), pp.1056~1060 (2009)
- Brown MS, "The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor", Cell, 89, pp.331~340 (1997)
- Weber LW, "Maintaining cholesterol homeostasis: sterol regulatory element- binding proteins", World J Gastroenterol, 10(21), pp.3081~3087 (2004)
- Horton JD, "SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver", J Clin Invest, 109, pp.1125~1131 (2002)
- Tong L, "Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery", Cell Mol Life Sci, 62(16), pp.1784~1803 (2005)
- Walker AK, "Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid", cholesterol regulator SREBP, 2010, pp.24, 1403~1417
- Li Y, "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice", Cell Metabolism, 13, pp.376~388 (2011)
- 이태호, "회춘양격산 물추출물의 항염증효과", 동의생리병리학회지, 23(6), pp.1341~1348 (2009), 대한동의병리학회
- Kim GJ, "Anti-allergic and anti- inflammatory analgesic effects of Hoechunyanggyeoksan", The J of Oriental Medical Surgery, Ophthalmology & Otolaryngology, 7(1), pp.1~13 (1994)
- Kang SW, "Experimental study on the anti-inflammatory and wound healing effect of hoichunyanggyuksan and yongseksan", The J of Oriental Medical Surgery, Ophthalmology & Otolaryngology, 12(1), pp.47~78 (1999)
- Hwang TG, "Jung-yak-bang-je-hyun-dae -yeon-gu-dae-jeon", pp.1256~ (1996), Science Publishing
- Heo JG, "Jung-ui-bang-je-hak", pp.174~175 (1991), Eum- yang -maek-gin Publishing
- Song IB, "Sa-sang-ui-hak", pp.397~398 (1997), Jip-mun-dang
- Marchi ED, "Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and Protein Kniase C", Oxidative Medicine and Cellular Longevity, 1013, pp.1~11 (2013)
- Savini I, "Obesity-associated oxidative stress: strategies finalized to improve redox state", Int J Mol Sci, 14, pp.10497~10537 (2013)
- Foufelle F, "New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c", Biochem J, 366, pp.377~391 (2002)
- Ferre P, "Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression", Biochemical Society Transactions, 29(4), pp.547~552 (2001)
- Horton JD, "Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis", Biochemical Society Transactions, 30(6), pp.1091~1095 (2001)
- Munday MR, "Regulation of mammalian acetyl-CoA carboxylase", Biochem Soc Trans, 30(6), pp.1059~1064 (2002)